- Previous Close
216.75 - Open
210.00 - Bid 207.00 x --
- Ask 217.50 x --
- Day's Range
210.00 - 210.00 - 52 Week Range
112.00 - 282.00 - Volume
40 - Avg. Volume
13,582 - Market Cap (intraday)
7.152B - Beta (5Y Monthly) 1.26
- PE Ratio (TTM)
140.00 - EPS (TTM)
1.50 - Earnings Date May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date May 18, 2016
- 1y Target Est
--
RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment in the Asia-Pacific, the Middle East, the Americas, Europe, and Africa. It develops and markets RayStation, a treatment planning system; RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy; and RayCare, an oncology information. In addition, it offers µ-RayStation, a software platform for planning and evaluation in small animal irradiation research; RayCommand, a treatment control system that serves as link between the treatment machine and the treatment planning and oncology information systems; and RayIntelligence, a cloud-based oncology analytics system that turns patient data into insights. Further, the company provides training courses related to its products. RaySearch Laboratories AB (publ) is headquartered in Stockholm, Sweden.
www.raysearchlabs.com375
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 0GRZ.IL
View MorePerformance Overview: 0GRZ.IL
Trailing total returns as of 4/9/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0GRZ.IL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0GRZ.IL
View MoreValuation Measures
Market Cap
7.44B
Enterprise Value
7.45B
Trailing P/E
36.49
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.23
Price/Book (mrq)
8.48
Enterprise Value/Revenue
6.25
Enterprise Value/EBITDA
28.59
Financial Highlights
Profitability and Income Statement
Profit Margin
5.58%
Return on Assets (ttm)
2.10%
Return on Equity (ttm)
7.99%
Revenue (ttm)
944.9M
Net Income Avi to Common (ttm)
52.69M
Diluted EPS (ttm)
1.50
Balance Sheet and Cash Flow
Total Cash (mrq)
246.23M
Total Debt/Equity (mrq)
76.51%
Levered Free Cash Flow (ttm)
155.04M